EDWARDS_LIFESCIENCES_LIMI - Accounts


Company Registration No. 03879325 (England and Wales)
EDWARDS LIFESCIENCES LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017
EDWARDS LIFESCIENCES LIMITED
COMPANY INFORMATION
Directors
Mr P L P Cappelle
Ms L Park
(Appointed 18 May 2018)
Mr R W A Sellers
Mr N Walker
Secretary
Mitre Secretaries Limited
Company number
03879325
Registered office
Cannon Place
78 Cannon Street
London
EC4N 6AF
Auditor
Craufurd Hale Audit Services Limited
Ground floor, Belmont Place
Belmont Road
MAIDENHEAD
SL6 6TB
Business address
3, The Sector
Newbury Business Park
London Road
Newbury
RG14 2PZ
EDWARDS LIFESCIENCES LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2 - 3
Directors' responsibilities statement
4
Independent auditor's report
5 - 6
Income statement
7
Statement of comprehensive income
8
Statement of financial position
9
Statement of changes in equity
10
Statement of cash flows
11
Notes to the financial statements
12 - 22
EDWARDS LIFESCIENCES LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2017
- 1 -

The directors present the strategic report for the year ended 31 December 2017.

Fair review of the business

Net sales were up on the previous year driven by strong sales within the Transcatheter Heart Valve (THV) product line. THV enjoyed further success from the third generation Sapien 3 Transcatheter Aortic Valve Implantation (TAVI) device that has enabled Edwards to take an even greater share of the UK & Irish TAVI market.

In addition, the Heart Valve Therapy division had early success from the newly launched Inspiris Resilia Aortic Valve Replacement device that introduced features that benefit both patient and clinician.

Principal risks and uncertainties

The principal risk facing the company arises from the fact that the majority of sales are made to the NHS and as a result are reliant on NHS purchasing activity and the on-going centralisation of its purchasing organisation. The company therefore operates in an environment where less costly products and treatments may be seen as an attractive way to save funds in the short term and so a highly innovative and specialised company such as Edwards must therefore demonstrate the importance of better outcomes and the longer term benefits that our products bring.

Development and performance
The company's financial postion at the year end was considered satisfactory.
Key performance indicators

The primary KPI is gross revenue, which has increased this year.

On behalf of the board

Mr N Walker
Director
16 July 2018
EDWARDS LIFESCIENCES LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2017
- 2 -

The directors present their annual report and financial statements for the year ended 31 December 2017.

Principal activities

The principal activity of the company is the distribution, on a commmission basis, of medical devices within the UK, as agent on behalf of a fellow subsidiary company within the Edwards Lifesciences Corporation group.

Branches

Throughout the current and previous year the company operated a branch in the Republic of Ireland.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Ms D E Botticelli
(Resigned 18 May 2018)
Mr P L P Cappelle
Ms L Park
(Appointed 18 May 2018)
Mr R W A Sellers
Mr N Walker
Results and dividends

The results for the year are set out on page 7.

Ordinary dividends were paid amounting to £1,300,000. The directors do not recommend payment of a final dividend.

Financial instruments
Liquidity risk

The company manages its cash and borrowing requirements in order to maximise interest income and minimise interest expense, whilst ensuring the company has sufficient liquid resources to meet the operating needs of the business.

Interest rate risk

The company is exposed to fair value interest rate risk on its fixed rate borrowings and cash flow interest rate risk on floating rate deposits, bank overdrafts and loans.

Foreign currency risk

The company’s principal foreign currency exposures arise from trading with overseas companies.

Credit risk

All customers who wish to trade on credit terms are subject to credit verification procedures.

Auditor

The auditor, Craufurd Hale Audit Services Limited, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

EDWARDS LIFESCIENCES LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 3 -
On behalf of the board
Mr N Walker
Director
16 July 2018
EDWARDS LIFESCIENCES LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2017
- 4 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

 

  •     select suitable accounting policies and then apply them consistently;

  •     make judgements and accounting estimates that are reasonable and prudent;

  •     state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

  •     prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

EDWARDS LIFESCIENCES LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF EDWARDS LIFESCIENCES LIMITED
- 5 -
Opinion

We have audited the financial statements of Edwards Lifesciences Limited (the 'company') for the year ended 31 December 2017 which comprise the income statement, the statement of comprehensive income, the statement of financial position, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

  •     give a true and fair view of the state of the company's affairs as at 31 December 2017 and of its profit for the year then ended;

  •     have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

  •     have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

  • the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or

  • the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company’s ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

  • the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

  • the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.

EDWARDS LIFESCIENCES LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF EDWARDS LIFESCIENCES LIMITED
- 6 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors' report.

 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

 

  •     adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

  •     the financial statements are not in agreement with the accounting records and returns; or

  •     certain disclosures of directors' remuneration specified by law are not made; or

  •     we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: http://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Christopher Krol FCA (Senior Statutory Auditor)
for and on behalf of Craufurd Hale Audit Services Limited
8 August 2018
Chartered Accountants
Statutory Auditor
Ground floor, Belmont Place
Belmont Road
MAIDENHEAD
SL6 6TB
EDWARDS LIFESCIENCES LIMITED
INCOME STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2017
- 7 -
2017
2016
Notes
£
£
Turnover
3
12,286,098
11,295,115
Cost of sales
(95,518)
(276,969)
Gross profit
12,190,580
11,018,146
Administrative expenses
(10,019,697)
(9,186,139)
Operating profit
4
2,170,883
1,832,007
Interest payable and similar expenses
7
(18,460)
(21,835)
Profit before taxation
2,152,423
1,810,172
Tax on profit
8
(418,819)
(447,480)
Profit for the financial year
1,733,604
1,362,692

The Income Statement has been prepared on the basis that all operations are continuing operations.

EDWARDS LIFESCIENCES LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2017
- 8 -
2017
2016
£
£
Profit for the year
1,733,604
1,362,692
Other comprehensive income
Currency translation differences
13,681
36,887
Total comprehensive income for the year
1,747,285
1,399,579
EDWARDS LIFESCIENCES LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2017
31 December 2017
- 9 -
2017
2016
Notes
£
£
£
£
Fixed assets
Tangible assets
10
750,561
368,413
Current assets
Debtors
12
9,931,105
11,243,294
Cash at bank and in hand
4,603,834
2,593,611
14,534,939
13,836,905
Creditors: amounts falling due within one year
13
(12,720,638)
(12,087,284)
Net current assets
1,814,301
1,749,621
Total assets less current liabilities
2,564,862
2,118,034
Provisions for liabilities
14
(37,486)
(37,943)
Net assets
2,527,376
2,080,091
Capital and reserves
Called up share capital
17
1
1
Capital contribution
119,608
119,608
Profit and loss reserves
2,407,767
1,960,482
Total equity
2,527,376
2,080,091
The financial statements were approved by the board of directors and authorised for issue on 16 July 2018 and are signed on its behalf by:
Mr N Walker
Director
Company Registration No. 03879325
EDWARDS LIFESCIENCES LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2017
- 10 -
Share capital
Capital contribution
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2016
1
119,608
1,560,903
1,680,512
Year ended 31 December 2016:
Profit for the year
-
-
1,362,692
1,362,692
Other comprehensive income:
Currency translation differences
-
-
36,887
36,887
Total comprehensive income for the year
-
-
1,399,579
1,399,579
Dividends
9
-
-
(1,000,000)
(1,000,000)
Balance at 31 December 2016
1
119,608
1,960,482
2,080,091
Year ended 31 December 2017:
Profit for the year
-
-
1,733,604
1,733,604
Other comprehensive income:
Currency translation differences
-
-
13,681
13,681
Total comprehensive income for the year
-
-
1,747,285
1,747,285
Dividends
9
-
-
(1,300,000)
(1,300,000)
Balance at 31 December 2017
1
119,608
2,407,767
2,527,376
EDWARDS LIFESCIENCES LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2017
- 11 -
2017
2016
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
21
4,379,360
886,626
Interest paid
(18,460)
(21,835)
Income taxes paid
(492,033)
(166,048)
Net cash inflow from operating activities
3,868,867
698,743
Investing activities
Purchase of tangible fixed assets
(572,549)
(109,330)
Proceeds on disposal of tangible fixed assets
13,905
56,730
Net cash used in investing activities
(558,644)
(52,600)
Financing activities
Dividends paid
(1,300,000)
(1,000,000)
Net cash used in financing activities
(1,300,000)
(1,000,000)
Net increase/(decrease) in cash and cash equivalents
2,010,223
(353,857)
Cash and cash equivalents at beginning of year
2,593,611
2,947,468
Cash and cash equivalents at end of year
4,603,834
2,593,611
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017
- 12 -
1
Accounting policies
Company information

Edwards Lifesciences Limited is a private company limited by shares incorporated in England and Wales. The registered office is Cannon Place, 78 Cannon Street, London, EC4N 6AF.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The financial statements are representative of an individual company not a group.

1.2
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover
Turnover represents commission receivable net of VAT, expenditure recharged to group companies and income generated from technical services.
1.4
Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Over shorter of lease term and asset life
Plant and machinery
Straight line over 10 years
Computer equipment
Straight line over 3- 4 years
Hospital equipment
Straight line over 2 - 5 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

From time to time, the company reviews the carrying amounts of the assets it places in hospitals to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the asset is written down.

EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies
(Continued)
- 13 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6
Cash at bank and in hand

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts, if there are any, are shown within borrowings in current liabilities.

1.7
Financial instruments

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are measured at transaction price.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies
(Continued)
- 14 -
Classification of financial liabilities

Financial liabilities are classified according to the substance of the contractual arrangements entered into. Apart from its Ordinary shares, the company has no equity instruments.

Basic financial liabilities

Basic financial liabilities, including trade and other payables, are recognised at transaction price.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value though profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.8
Equity instruments

The only equity instruments are the Ordinary shares. Dividends payable are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax
Deferred taxation is provided at appropriate rates on all timing differences using the liability method only to the extent that, in the opinion of the directors, there is a reasonable probability that a liability or asset will crystallise in the foreseeable future and the amounts are material.
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense. The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

If termination benefits become payable they are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies
(Continued)
- 15 -
1.11
Retirement benefits
The pension costs charged in the financial statements represent the contributions payable by the company during the year in accordance with FRS 17.
1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

1.13
Foreign exchange

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date set by the group, because the majority are inter-company balances. Transactions in foreign currencies are recorded at the rates set for each month on a Europe-wide basis within the group. Conversion differences are taken to the Income Statement. Translation differences relating to the Irish branch are reflected in the Statement of Comprehensive Income.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Turnover and other revenue

An analysis of the company's turnover is as follows:

2017
2016
£
£
Turnover analysed by class of business
Distribution, on a commission basis, of medical devices within the UK and Ireland, as agent on behalf of a fellow subsidiary within the Edwards Lifesciences Corporation group
10,076,448
8,678,328
Intercompany charges
2,165,804
2,439,601
Freight income
43,846
177,186
12,286,098
11,295,115
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
3
Turnover and other revenue
(Continued)
- 16 -
2017
2016
£
£
Turnover analysed by geographical market
United Kingdom
9,088,795
7,931,543
Republic of Ireland
1,031,499
923,972
Europe
2,165,804
2,439,600
12,286,098
11,295,115
4
Operating profit
2017
2016
Operating profit for the year is stated after charging/(crediting):
£
£
Exchange losses/(gains)
(3,477)
1,670
Fees payable to the company's auditors for the audit of the company's financial statements
11,100
14,500
Depreciation of owned tangible fixed assets
176,496
149,175
Cost of spares recognised as an expense
(1,447)
160,203
Operating lease charges
343,415
337,017
5
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2017
2016
Number
Number
Directors
4
4
Administration
23
19
Sales
24
30
51
53

Their aggregate remuneration comprised:

2017
2016
£
£
Wages and salaries
4,635,535
4,223,927
Social security costs
647,965
632,791
Pension costs
294,958
309,774
5,578,458
5,166,492
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 17 -
6
Directors' remuneration
2017
2016
£
£
Remuneration for qualifying services
117,175
116,171
Company pension contributions to defined contribution schemes
11,209
10,856
128,384
127,027

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 1 (2016 - 1).

7
Interest payable and similar expenses
2017
2016
£
£
Interest on financial liabilities measured at cost:
Interest payable to group undertakings
18,460
21,835
8
Taxation
2017
2016
£
£
Current tax
UK corporation tax on profits for the current period
488,539
413,048
Adjustments in respect of prior periods
(69,231)
34,432
Total current tax
419,308
447,480
Deferred tax
Origination and reversal of timing differences
(489)
-
Total tax charge
418,819
447,480

When they change, UK tax rates change on 1 April each year. In what follows, the average rate for each year has been calculated.

EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
8
Taxation
(Continued)
- 18 -

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2017
2016
£
£
Profit before taxation
2,152,423
1,810,172
Expected tax charge based on the standard rate of corporation tax in the UK of 19.00% (2016: 20.00%)
408,960
362,034
Tax effect of expenses that are not deductible in determining taxable profit
56,226
16,865
Effect of change in corporation tax rate
5,419
-
Under/(over) provided in prior years
(69,231)
-
Capital allowances
(47,689)
(7,969)
(Under)/over provided in current year
65,623
76,550
Deferred tax movement
(489)
-
Taxation charge for the year
418,819
447,480
9
Dividends
2017
2016
£
£
Interim paid
1,300,000
1,000,000
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 19 -
10
Tangible fixed assets
Leasehold improvements
Plant and machinery
Computer equipment
Hospital equipment
Total
£
£
£
£
£
Cost
At 1 January 2017
51,082
89,105
19,399
1,379,241
1,538,827
Additions
267,132
198,558
13,762
93,097
572,549
Disposals
(51,082)
(88,456)
(16,280)
(129,925)
(285,743)
At 31 December 2017
267,132
199,207
16,881
1,342,413
1,825,633
Depreciation and impairment
At 1 January 2017
51,081
86,516
19,399
1,013,418
1,170,414
Depreciation charged in the year
11,130
10,289
1,526
153,551
176,496
Eliminated in respect of disposals
(51,081)
(86,228)
(16,280)
(118,249)
(271,838)
At 31 December 2017
11,130
10,577
4,645
1,048,720
1,075,072
Carrying amount
At 31 December 2017
256,002
188,630
12,236
293,693
750,561
At 31 December 2016
1
2,589
-
365,823
368,413
11
Financial instruments
2017
2016
£
£
Carrying amount of financial assets
Debt instruments measured at amortised cost
9,017,712
10,455,630
Carrying amount of financial liabilities
Measured at amortised cost
11,609,379
11,162,609
12
Debtors
2017
2016
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
9,014,212
10,447,616
Other debtors
3,500
8,014
Prepayments and accrued income
913,393
787,664
9,931,105
11,243,294
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 20 -
13
Creditors: amounts falling due within one year
2017
2016
£
£
Trade creditors
159,386
92,884
Amounts due to group undertakings
9,482,435
9,493,141
Corporation tax
233,520
306,277
Other taxation and social security
877,739
618,398
Other creditors
60,076
68,793
Accruals and deferred income
1,907,482
1,507,791
12,720,638
12,087,284
14
Provisions for liabilities
2017
2016
Notes
£
£
Deferred tax liabilities
15
37,486
37,943
15
Deferred taxation

Deferred tax assets and liabilities are offset where the company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:

Liabilities
Liabilities
2017
2016
Balances:
£
£
Accelerated capital allowances
37,486
37,943
2017
Movements in the year:
£
Liability at 1 January 2017
37,943
Credit to profit or loss
(457)
Liability at 31 December 2017
37,486
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 21 -
16
Retirement benefit schemes
2017
2016
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
294,958
309,774

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

17
Share capital
2017
2016
£
£
Ordinary share capital
Issued and fully paid
1 Ordinary shares of £1 each
1
1
1
1
18
Operating lease commitments
Lessee

Operating lease payments represent rentals payable by the company for its properties and for vehicle leases.

 

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

2017
2016
£
£
Within one year
199,915
130,397
Between two and five years
747,392
122,411
In over five years
920,008
-
1,867,315
252,808
19
Capital commitments

Amounts contracted for but not provided in the financial statements:

2017
2016
£
£
Acquisition of tangible fixed assets and fitting out of new premises
-
424,809
EDWARDS LIFESCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 22 -
20
Controlling party

The immediate parent company is Edwards Lifesciences Holding B.V., which is incorporated in The Netherlands.

The ultimate parent company is Edwards Lifesciences Corporation. It is incorporated in the USA.

The smallest group of undertakings for which group accounts are drawn up is Edwards Lifesciences B.V., which is registered in The Netherlands. Copies of the group accounts can be obtained from the company at Verlengde Poolesweg 16, 4818CL, Breda.

 

The largest group of undertakings for which group accounts are drawn up is Edwards Lifesciences Corporation, whose registered office is at One Edwards Way, Irvine, California 92614. Copies of the consolidated accounts can be obtained from that address and are available online at edwards.com.

21
Cash generated from operations
2017
2016
£
£
Profit for the year after tax
1,733,604
1,362,692
Adjustments for:
Taxation charged
418,819
447,480
Finance costs
18,460
21,835
Depreciation and impairment of tangible fixed assets
176,496
149,175
Foreign exchange gains on cash equivalents
13,681
36,887
Movements in working capital:
Decrease/(increase) in debtors
1,312,189
(1,328,226)
Increase in creditors
706,111
196,783
Cash generated from operations
4,379,360
886,626
2017-12-312017-01-01falseCCH SoftwareCCH Accounts Production 2018.220Mitre Secretaries Limited038793252017-01-012017-12-3103879325bus:Director32017-01-012017-12-3103879325bus:Director42017-01-012017-12-3103879325bus:Director52017-01-012017-12-3103879325bus:Director62017-01-012017-12-3103879325bus:CompanySecretary12017-01-012017-12-3103879325bus:Director22017-01-012017-12-3103879325bus:RegisteredOffice2017-01-012017-12-31038793252017-12-31038793252016-01-012016-12-31038793252016-12-3103879325core:LeaseholdImprovements2017-12-3103879325core:PlantMachinery2017-12-3103879325core:ComputerEquipment2017-12-3103879325core:MotorVehicles2017-12-3103879325core:LeaseholdImprovements2016-12-3103879325core:PlantMachinery2016-12-3103879325core:MotorVehicles2016-12-3103879325core:CurrentFinancialInstruments2017-12-3103879325core:CurrentFinancialInstruments2016-12-3103879325core:ShareCapital2017-12-3103879325core:ShareCapital2016-12-3103879325core:OtherMiscellaneousReserve2017-12-3103879325core:OtherMiscellaneousReserve2016-12-3103879325core:RetainedEarningsAccumulatedLosses2017-12-3103879325core:RetainedEarningsAccumulatedLosses2016-12-3103879325core:ShareCapitalcore:RestatedAmount2015-12-3103879325core:OtherMiscellaneousReservecore:RestatedAmount2015-12-3103879325core:RetainedEarningsAccumulatedLossescore:RestatedAmount2015-12-3103879325core:RestatedAmount2015-12-3103879325core:ShareCapitalOrdinaryShares2017-12-3103879325core:ShareCapitalOrdinaryShares2016-12-3103879325core:RetainedEarningsAccumulatedLosses2016-01-012016-12-3103879325core:LeaseholdImprovementscore:LeasedAssetsHeldAsLessee2017-01-012017-12-3103879325core:PlantMachinery2017-01-012017-12-3103879325core:ComputerEquipment2017-01-012017-12-3103879325core:MotorVehicles2017-01-012017-12-3103879325core:UKTax2017-01-012017-12-3103879325core:UKTax2016-01-012016-12-310387932512017-01-012017-12-310387932522017-01-012017-12-310387932512016-01-012016-12-310387932532017-01-012017-12-310387932522016-01-012016-12-310387932542017-01-012017-12-3103879325core:LeaseholdImprovements2016-12-3103879325core:PlantMachinery2016-12-3103879325core:ComputerEquipment2016-12-3103879325core:MotorVehicles2016-12-31038793252016-12-3103879325core:LeaseholdImprovements2017-01-012017-12-3103879325bus:OrdinaryShareClass12017-01-012017-12-3103879325bus:OrdinaryShareClass12017-12-3103879325bus:PrivateLimitedCompanyLtd2017-01-012017-12-3103879325bus:FRS1022017-01-012017-12-3103879325bus:Audited2017-01-012017-12-3103879325bus:FullAccounts2017-01-012017-12-31xbrli:purexbrli:sharesiso4217:GBP